Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma

NCT03841201 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib
DRUG: Nivolumab

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

[object Object]
[object Object]